Your Dose of Cannabis Education
Your Dose of Cannabis Education
Only have a minute but want to Learn something every day™? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.
Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education.
Wake up every morning and get your dose of unbiased evidence-based cannabis education!
Share:
2026-01-30
How does cannabis consumption alter appetite and metabolism?
Cannabinoids influence both appetite and metabolism through CB1- and CB2-receptor pathways.
While CB1 activation increases appetite and promotes energy storage, it also reduces insulin secretion and may contribute to glucose intolerance.
Studies suggest that the endocannabinoid system modulates taste sensationdi Marzo, V., Piscitelli, F., & Mechoulam, R. (2011). Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. In M. Schwanstecher (Ed.), Diabetes - Perspectives in Drug Therapy (Handbook of Experimental Pharmacology, Vol. 203, pp. 75-104). Springer. https://doi.org/10.1007/978-3-642-17214-4_11
Farrimond, J. A., Mercier, M. S., Whalley, B. J., & Williams, C. M. (2011). Cannabis sativa and the endogenous cannabinoid system: Therapeutic potential for appetite regulation. Phytotherapy Research, 25(2), 170-188. https://doi.org/10.1002/ptr.3265
Matias, I., Bisogno, T., & di Marzo, V. (2006). Endogenous cannabinoids in the brain and peripheral tissues: Regulation of their levels and control of food intake. International Journal of Obesity, 30(Suppl. 1), S7-S12. https://doi.org/10.1038/sj.ijo.0803270
Tibirica, E. (2010). The multiple functions of the endocannabinoid system: A focus on the regulation of food intake. Diabetology & Metabolic Syndrome, 2, 5-10. https://doi.org/10.1186/1758-5996-2-5
2026-01-29
In adults, cannabis use is not typically associated with a decrease in respiratory drive. Is the same true for pediatric patients?
No - in the case of pediatric cannabis exposures, the common findings include confusion, agitation, lethargy, tachycardia, ataxia, and vomiting, BUT "more concerning findings are hypotension, coma, respiratory depression, and seizure, which occur in Pepin, L. C., Simon, M. W., Banerji, S., et al. (2023). Toxic tetrahydrocannabinol (THC) dose in pediatric cannabis edible ingestions. Pediatrics, 152(3), e2023061374. https://doi.org/10.1542/peds.2023-061374
2026-01-28
Is dizziness a common side effect of THC?
There is good evidence that dizziness is among the most common non-serious adverse neurological side-effects of medical cannabinoids. For example, a systematic review covering a 40-year span of studies found that dizziness occurred in 15.5% of patients exposed to cannabinoid therapy.Wang, T., Collet, J. P., Shapiro, S., & Ware, M. A. (2008). Adverse effects of medical cannabinoids: A systematic review. Canadian Medical Association Journal, 178(13), 1669-1678. https://doi.org/10.1503/cmaj.071178
2026-01-27
Some cannabis consumers present to the ER with severe anxiety or psychosis requiring pharmacologic management. What medicines are approved to treat the anxiety or psychosis associated with cannabis use?
Although most cases of cannabis intoxication are mild and self-limited, some individuals present to the ER with severe anxiety, agitation, or psychosis requiring pharmacologic management. No medications are approved specifically for treating the anxiety, panic, or psychosis associated with cannabis intoxication. "Severe agitation or anxiety is controlled with benzodiazepines. Psychosis usually responds to a second-generation antipsychotic agent, and the dosage can be adjusted to account for the severity of the psychosis." (Gorelick)Gorelick, D. A. (2023). Cannabis-related disorders and toxic effects. The New England Journal of Medicine, 389, 2267-2275. https://doi.org/10.1056/NEJMra2306065 Weinstein, A. M., & Gorelick, D. A. (2011). Pharmacological treatment of cannabis dependence. Current Pharmaceutical Design, 17(14), 1351-1358.
2026-01-26
Does THC bind to plasma proteins?
According to the FDA's highlights of prescribing information for an orally administered THC-based product (Marinol), THC is highly bound to plasma proteins and may displace other drugs that also bind to these proteins. Adverse reactions can occur when THC is used concurrently with other highly protein-bound or narrow therapeutic index drugs, such as warfarin, cyclosporine, or amphotericin B, particularly when initiating or increasing the THC dose. Food and Drug Administration (FDA). (2005). Marinol (dronabinol) capsules: Highlights of prescribing information.U.S. Department of Health & Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf
Learn something every day™ in your 
feed…
Our courses
CBD in Clinical Care V2
A Nationally Approved CME/CE Medical Marijuana Course V2
Cannabis Essentials CME/CE Bundle
New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.